Patheon names interim head of pharmaceutical development services and cso
Doug Mendenhall has been appointed as interim head of Patheon's pharmaceutical development services unit and chief scientific officer.
Doug Mendenhall has been appointed as interim head of Patheon's pharmaceutical development services unit and chief scientific officer.
Dr Mendenhall will work under contract until such time that a permanent president is appointed, but will be retained as an advisor to the company. Dr Mendenhall is a 35-year veteran in the pharmaceutical industry, having held executive positions at Abbott, GlaxoSmithKline and most recently, Merck.